H. Lyons

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

L. Trippa, N. Munshi, J. Laubach, 2019, Blood.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

L. Trippa, N. Munshi, J. Laubach, 2018, British journal of haematology.